What is it about?
The paper describes a promising new treatment for patients with triple-negative breast cancer, a subform of breast cancer which currently lacks a targeted therapy
Featured Image
Why is it important?
Triple-negative breast cancer currently lacks a targeted therapy. APR-246 which targets mutant p53 (present in 80% of triple-negative breast cancers) is a potential new therapy for these patients.
Read the Original
This page is a summary of: Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?, International Journal of Cancer, September 2016, Wiley,
DOI: 10.1002/ijc.30425.
You can read the full text:
Contributors
The following have contributed to this page
